Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.41 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15127544 | 0.86 | ACHE (0.49) | CHRM3CHRM2CHRM1KMT2ALMNA | |
| SCHEMBL27915228 | 0.80 | SMN1; SMN2 (0.41) | CHRM3CHRM2CHRM1MEN1KMT2A | |
| SCHEMBL9967818 | 0.76 | CHRM3 (0.45) | CHRM3CHRM2CHRM1MEN1KMT2A | |
| SCHEMBL4884492 | 0.76 | CHRM3 (0.70) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3669017 | 0.76 | CHRM3 (0.70) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3652874 | 0.70 | CYP2D6 (0.48) | CHRM3CHRM2CHRM1KMT2AKDM4E | |
| SCHEMBL8917126 | 0.69 | L3MBTL3 (0.84) | L3MBTL3MEN1KMT2ACCR5KDM4E | |
| SCHEMBL3668368 | 0.67 | L3MBTL3 (0.59) | L3MBTL3MEN1KMT2ACCR5CDYL | |
| SCHEMBL3635391 | 0.67 | L3MBTL3 (0.48) | L3MBTL3CHRM3CHRM2CHRM1CDYL | |
| SCHEMBL2374558 | 0.67 | OPRD1 (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216971-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216971-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216971-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8815907-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815907-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815907-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130281489-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20120232053-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8202891-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202891-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202891-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2146957-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008133900-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008133900-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281489-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | L3MBTL3 3520/4885CHRM3 4/4885CHRM2 1/4885 |
| US-20120232053-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | L3MBTL3 3520/4885CHRM3 4/4885CHRM2 1/4885 |
| US-20080269190-A1 | Chronic obstructive pulmonary disease; asthma | CHRM2, CHRM5, CHRM3 | L3MBTL3 2817/4885CHRM3 3/4885CHRM2 1/4885 |
| US-20140329857-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | L3MBTL3 3520/4885CHRM3 4/4885CHRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.